Why Farbe Firma is the Top Manufacturer of Acyclovir for Injection
- Maulik Sudani
- 4 hours ago
- 8 min read
Last Updated: June 18, 2026
TL;DR: Acyclovir for Injection — a sterile lyophilized powder of acyclovir sodium, a synthetic purine (guanosine) nucleoside analogue antiviral, reconstituted and then diluted for slow intravenous infusion and supplied commonly as 250 mg, 500 mg and 1000 mg vials — is the hospital standard for severe herpes simplex (HSV) infections, herpes simplex encephalitis, neonatal herpes and varicella-zoster (VZV) infections in immunocompromised patients. Because the patient is frequently severely ill or immunocompromised and the reconstituted solution is intensely alkaline (about pH 11) and can crystallise in the renal tubules if infused too quickly or without adequate hydration, each vial must deliver an exact, sterile, particulate-free dose that reconstitutes cleanly at the correct high pH, with the assay, the related-substance and degradation profile (notably guanine), residual moisture, reconstitution time and clarity, solution pH, fill content, low particulate and endotoxin, a validated lyophilization and sterilisation route and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Acyclovir for Injection at our Gujarat, India facility and supplies it to infectious-disease, neurology, neonatology, oncology and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Synthetic purine (guanosine) nucleoside analogue antiviral (acyclovir sodium) — Acyclovir for Injection is given by slow intravenous infusion over about an hour, with adequate hydration, for severe herpes simplex infections, herpes simplex encephalitis, neonatal herpes and varicella-zoster infections in immunocompromised patients, where prompt, accurately dosed therapy is decisive.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated high-pH compounding, freeze-drying and vial filling lines, control of the stability-indicating assay, the related-substance and degradation profile (notably guanine), solution pH, residual moisture by Karl Fischer, reconstitution time and clarity, fill content, particulate and endotoxin, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, lyophilization-cycle, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile lyophilized and powder-for-injection contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready vial packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Acyclovir for Injection Demands a Premium Manufacturer
Acyclovir for Injection holds a critical, time-sensitive place in infectious-disease, neurology and neonatology services across every market. It is the intravenous antiviral that clinicians reach for when a herpes infection turns dangerous — herpes simplex encephalitis, disseminated or neonatal herpes, and varicella-zoster in an immunocompromised patient — situations where the speed and accuracy of treatment can decide whether a patient survives without lasting harm. As a synthetic guanosine nucleoside analogue that is selectively activated inside virus-infected cells, acyclovir lets a treating team deliver high, reliable antiviral exposure intravenously when the oral route is too slow or the illness too severe. In each of these settings the dose delivered from each vial must be exact, sterile, particulate-free and reliably the same from unit to unit, because outcome in a life-threatening viral illness depends on a precise, reproducible dose given without delay.
That clinical reality places real demands on the manufacturer. Acyclovir is poorly soluble as the free base, so the injectable is formulated as the sodium salt at a high, alkaline pH — the reconstituted concentrate sits at around pH 11 — and is supplied as a lyophilized powder that must be reconstituted and then further diluted before a slow infusion given over roughly an hour with good hydration, because rapid infusion or dehydration can let the drug crystallise in the renal tubules and injure the kidney. The manufacturer must therefore compound at a tightly controlled alkaline pH, run a validated freeze-drying cycle, and seal the vials under low humidity with residual moisture held within a defined limit so the cake stays stable and reconstitutes cleanly. The assay of acyclovir must be exact; the related-substance and degradation profile — with guanine as the principal degradation product — must stay within tight limits; the reconstitution time, clarity and solution pH must be controlled so each vial yields a clear, correctly buffered solution; and the product must be free of visible and sub-visible particulates and low in endotoxin. Choosing an Acyclovir for Injection manufacturer that treats high-pH compounding, the lyophilization cycle and residual-moisture control, the stability-indicating assay, reconstitution and particulate control and container-closure integrity as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Acyclovir for Injection Manufacturer Apart
A world-class manufacturer of Acyclovir for Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of acyclovir with related-substance and degradation control by validated HPLC — tracking guanine and other process and degradation impurities — that a high-pH antiviral demands, a robust, validated lyophilization and aseptic fill process that protects sterility, cake quality and reconstitution behaviour in an alkaline, moisture-sensitive product, and tender-ready dossier support for a high-volume hospital-formulary antiviral procured through pharmacy and ministry-of-health channels. It starts with the active — pharmacopoeial-grade acyclovir (and the sodium salt formed in situ or supplied) sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend the assay, the high pH and the integrity of a freeze-dried cake. The bulk solution is compounded in water-for-injection with the alkalising agent that forms acyclovir sodium and holds the controlled alkaline pH at which the drug stays soluble and stable, sterile-filtered through 0.22 µm membrane, filled into vials under ISO Class 5 conditions, and lyophilized under a validated cycle, with the vials sealed under low humidity and residual moisture confirmed by Karl Fischer, the whole moisture-sensitive workflow protected from ambient humidity and light, with the validated sterilisation strategy — aseptic processing of a sterile-filtered bulk with a validated freeze-drying cycle — locked in the master batch record. Filled vials are 100 % inspected for fill, cake appearance, seal and particulate defects; in-process and release testing confirm the assay of acyclovir by validated HPLC, the related-substance and degradation profile (notably guanine), solution pH after reconstitution, residual moisture, reconstitution time and clarity, deliverable content, visible and sub-visible particulate matter, and that endotoxin is held well within limits so the solution is safe for intravenous infusion. Because the product is alkaline, moisture-sensitive and light-sensitive, the high-pH compounding, residual-moisture control and container-closure integrity are validated together so assay, pH and reconstitution behaviour stay within specification across shelf life.
Quality Systems Behind Every Acyclovir for Injection
Every Farbe Firma Acyclovir for Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of acyclovir against pharmacopoeial reference standards, control of related substances and degradation products (notably guanine) by HPLC, solution pH after reconstitution, reconstitution time and clarity and colour of the reconstituted solution, residual moisture by Karl Fischer, deliverable content, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the vial format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental and humidity monitoring, validated sterilisation, depyrogenation and lyophilization equipment, validated aseptic filling lines with 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because acyclovir for injection is an intensely alkaline, moisture-sensitive freeze-dried product and the assay, pH, residual moisture, reconstitution behaviour, particulate and endotoxin burden drive both efficacy and safety, we treat the stability-indicating HPLC assay, the residual moisture, the reconstitution time and the solution pH as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (25 °C / 60 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge, and reconstitution and in-use stability are established to support intravenous preparation and slow infusion in hospital practice.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Acyclovir for Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad anti-infective and antiviral small-volume parenteral portfolio alongside our wider hospital range. For Acyclovir for Injection specifically, we supply the 250 mg, 500 mg and 1000 mg lyophilized vials under WHO-GMP conditions, with country-specific strengths, fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the stability-indicating-assay, related-substance, residual-moisture, lyophilization-cycle, reconstitution, sterilisation and container-closure data package — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, lyophilization-cycle, sterilisation and container-closure reports, translated package inserts and artwork — including hydration and slow-infusion administration warnings — for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Acyclovir for Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding, filling and lyophilization suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, stability-indicating assay development, related-substance and degradation control including guanine, high-pH compounding and acyclovir-sodium formation, lyophilization-cycle design and residual-moisture control, reconstitution-time and reconstituted-solution clarity and pH, the choice of aseptic processing for an alkaline freeze-dried antiviral, deliverable-content accuracy, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a life-saving antiviral where assay accuracy, high-pH and moisture control, reconstitution behaviour and particulate control directly govern both efficacy and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Acyclovir for Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Acyclovir for Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, dedicated high-pH compounding, freeze-drying and vial filling lines under low-humidity control, validated sterilisation, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Acyclovir for Injection do you supply?
Our standard presentations are the 250 mg, 500 mg and 1000 mg lyophilized vials of acyclovir sodium, reconstituted and diluted for slow intravenous infusion. Custom strengths, fill configurations, vial formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Acyclovir for Injection mainly used for?
Acyclovir for Injection is used for severe herpes simplex infections, herpes simplex encephalitis, neonatal herpes and varicella-zoster infections in immunocompromised patients. It is a synthetic guanosine nucleoside analogue antiviral given by slow intravenous infusion with adequate hydration; Farbe Firma verifies the assay, related substances, reconstituted-solution pH and clarity, residual moisture, deliverable content, particulate matter and endotoxin at release so each vial delivers a precise, reproducible dose.
Can Farbe Firma support country-specific registrations for Acyclovir for Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, lyophilization-cycle, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Acyclovir for Injection contract manufacturing?
MOQs vary by strength, vial size, lyophilization-cycle requirements, label complexity and dossier requirements. For our lyophilized antiviral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments